Amid a roller-coaster end to 2024 for the stock market, dividend-paying stocks continued to lag the broader market. However, ...

Pfizer (PFE) reachead $26.91 at the closing of the latest trading day, reflecting a -0.83% change compared to its last close.

For fiscal 2025, management expects sales to range between $147 billion and $151 billion, while adjusted EPS is forecast to ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

Vaccine stocks received a major and sudden boost on January 7, 2025. Here's why these companies are experiencing tailwinds in ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

Moderna’s current price is less than $20 below the psychologically significant $50 price level. Traders often focus on these ...

Pfizer Inc. closed $4.65 short of its 52-week high ($31.54), which the company reached on July 30th.

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.59 which represents a decrease of $-0.02 or -0.08% from the prior close of $26.61. The stock opened at $26.7 and touched a low of ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

A patient-led study examines the potential of extended Paxlovid courses for Long COVID relief, documenting varied outcomes and emphasizing the need for clinical trials.

Pfizer Inc. (NYSE:PFE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings ...